268 related articles for article (PubMed ID: 15679514)
1. Computerized tremor analysis of valproate-induced tremor: a comparative study of controlled-release versus conventional valproate.
Rinnerthaler M; Luef G; Mueller J; Seppi K; Wissel J; Trinka E; Bauer G; Poewe W
Epilepsia; 2005 Feb; 46(2):320-3. PubMed ID: 15679514
[TBL] [Abstract][Full Text] [Related]
2. Conversion from delayed-release sodium valproate to extended-release sodium valproate: initial results and long-term follow-up.
McCabe PH; Michel NC; McNew CD; Lehman EB
Epilepsy Behav; 2006 May; 8(3):601-5. PubMed ID: 16678766
[TBL] [Abstract][Full Text] [Related]
3. Seizure control and side-effect profile after switching adult epileptic patients from standard to extended-release divalproex sodium.
Pierre-Louis SJ; Brannegan RT; Evans AT
Clin Neurol Neurosurg; 2009 Jun; 111(5):437-41. PubMed ID: 19181439
[TBL] [Abstract][Full Text] [Related]
4. Influence of major antiepileptic drugs on attention, reaction time, and speed of information processing: results from a randomized, double-blind, placebo-controlled withdrawal study of seizure-free epilepsy patients receiving monotherapy.
Hessen E; Lossius MI; Reinvang I; Gjerstad L
Epilepsia; 2006 Dec; 47(12):2038-45. PubMed ID: 17201701
[TBL] [Abstract][Full Text] [Related]
5. Successful initiation of combined therapy with valproate sodium injection and divalproex sodium extended-release tablets in the epilepsy monitoring unit.
Boggs JG; Preis K
Epilepsia; 2005 Jun; 46(6):949-51. PubMed ID: 15946337
[TBL] [Abstract][Full Text] [Related]
6. Short-term efficacy and safety of valproate sustained-release formulation in newly diagnosed partial epilepsy VIPe-study. A multicenter observational open-label study.
Deleu D; Al-Hail H; Mesraoua B; Mahmoud HA;
Saudi Med J; 2007 Sep; 28(9):1402-7. PubMed ID: 17768469
[TBL] [Abstract][Full Text] [Related]
7. [Valproate sustained release in the treatment of epilepsy].
Stefan H; Fraunberger B
Fortschr Neurol Psychiatr; 2005 Nov; 73(11):681-6. PubMed ID: 16283612
[TBL] [Abstract][Full Text] [Related]
8. Clinical and surface EMG characteristics of valproate induced tremors.
Mehndiratta MM; Satyawani M; Gupta S; Khwaja GA
Electromyogr Clin Neurophysiol; 2005; 45(3):177-82. PubMed ID: 15981690
[TBL] [Abstract][Full Text] [Related]
9. Once-daily dosing is appropriate for extended-release divalproex over a wide dose range, but not for enteric-coated, delayed-release divalproex: evidence via computer simulations and implications for epilepsy therapy.
Reed RC; Dutta S; Liu W
Epilepsy Res; 2009 Dec; 87(2-3):260-7. PubMed ID: 19892524
[TBL] [Abstract][Full Text] [Related]
10. Valproate-induced thrombocytopenia: a prospective monotherapy study.
Nasreddine W; Beydoun A
Epilepsia; 2008 Mar; 49(3):438-45. PubMed ID: 18031547
[TBL] [Abstract][Full Text] [Related]
11. Safety of rapid intravenous loading of valproate.
Limdi NA; Knowlton RK; Cofield SS; Ver Hoef LW; Paige AL; Dutta S; Faught E
Epilepsia; 2007 Mar; 48(3):478-83. PubMed ID: 17319914
[TBL] [Abstract][Full Text] [Related]
12. The frequency of reversible parkinsonism and cognitive decline associated with valproate treatment: a study of 364 patients with different types of epilepsy.
Ristić AJ; Vojvodić N; Janković S; Sindelić A; Sokić D
Epilepsia; 2006 Dec; 47(12):2183-5. PubMed ID: 17201721
[TBL] [Abstract][Full Text] [Related]
13. Thyroid function in children with epilepsy treated with sodium valproate monotherapy: a prospective study.
Attilakos A; Katsarou E; Prassouli A; Mastroyianni S; Voudris K; Fotinou A; Garoufi A
Clin Neuropharmacol; 2009; 32(1):32-4. PubMed ID: 18978499
[TBL] [Abstract][Full Text] [Related]
14. [Valproate induced parkinsonism].
Park-Matsumoto YC; Tazawa T
No To Shinkei; 1998 Jan; 50(1):81-4. PubMed ID: 9493204
[TBL] [Abstract][Full Text] [Related]
15. Quantitative analysis of motor performance in epilepsy patients treated with valproate.
Farkas Z; Gulyás S; Molnár R; Szirmai I; Kamondi A
Seizure; 2010 Apr; 19(3):173-7. PubMed ID: 20167509
[TBL] [Abstract][Full Text] [Related]
16. Valproate protein binding following rapid intravenous administration of high doses of valproic acid in patients with epilepsy.
Dutta S; Faught E; Limdi NA
J Clin Pharm Ther; 2007 Aug; 32(4):365-71. PubMed ID: 17635338
[TBL] [Abstract][Full Text] [Related]
17. [Acceptability and tolerance of sodium valproate, a new sustained-action granule formulation, in monotherapy for epileptic children from 3 years old].
Motte J; Pedespan JM; Sevestre M; Chiron C;
Arch Pediatr; 2005 Oct; 12(10):1533-9. PubMed ID: 16099147
[TBL] [Abstract][Full Text] [Related]
18. Effects of the abrupt switch from solution to modified-release granule formulation of valproate.
Verrotti A; Nanni G; Agostinelli S; Alleva ET; Aloisi P; Franzoni E; Spalice A; Chiarelli F; Coppola G
Acta Neurol Scand; 2012 Mar; 125(3):e14-8. PubMed ID: 21707552
[TBL] [Abstract][Full Text] [Related]
19. Effect of intracerebroventricular continuous infusion of valproic acid versus single i.p. and i.c.v. injections in the amygdala kindling epilepsy model.
Serralta A; Barcia JA; Ortiz P; Durán C; Hernández ME; Alós M
Epilepsy Res; 2006 Jul; 70(1):15-26. PubMed ID: 16616829
[TBL] [Abstract][Full Text] [Related]
20. Insulin-related metabolic changes during treatment with valproate in patients with epilepsy.
Pylvänen V; Pakarinen A; Knip M; Isojärvi J
Epilepsy Behav; 2006 May; 8(3):643-8. PubMed ID: 16600693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
